Aronia melanocarpa

Aronia melanocarpa (Black Chokeberry)

1. Identity, Botanical Classification, and Common Preparations

Aronia melanocarpa (Michx.) Elliott (family Rosaceae), commonly known as black chokeberry, is a shrub native to North America, of which the fresh fruits are not typically consumed directly owing to their bitter taste. It is a Rosaceae species native to eastern North America that has long been recognized as both a food and medicinal plant.

Aronia melanocarpa is also known as black chokeberry or black-seeded chokeberry. The shrub belongs to the rose family (Rosaceae). The other main Aronia species is Aronia arbutifolia, or red chokeberry. Both species are native to North America but can be told apart by the colour of their mature fruits. A hybrid cultivar developed by the Russian botanist Ivan Michurin, known as Aronia mitschurinii (or ×Sorbaronia mitschurinii), is widely grown for commercial production, particularly in Eastern Europe.

It is a deciduous shrub belonging to the Rosaceae family, widely cultivated for its fruits, which are distinguished by an exceptionally high content of bioactive polyphenols. The chemical composition of Aronia berries is unique, encompassing anthocyanins, predominantly cyanidin-3-galactoside, phenolic acids such as chlorogenic and neochlorogenic acid, and significant amounts of proanthocyanidins — condensed tannins with varying degrees of polymerization.

European countries — first Russia, then Scandinavia and later Poland and Austria — took up propagation. Poland now produces 80% of today's commercially used berries.

The berry is commercially available in a range of preparations. Fresh and unprocessed black aronia berries are rarely consumed due to their distinct astringent and bitter taste. It has been employed for various purposes throughout history, being exploited both for its nutritional properties (functional foods, beverages, food preservatives, and natural food colorants) and for its therapeutic benefits. Preparations include frozen berries, dried berries, and evaporated juice. The rich phytochemical profile of aronia supports diverse applications in the agri-food sector, including sports nutrition products, natural antioxidant additives, natural pigments, food preservation, and food coloring. Concentrated standardized extracts, powders, capsules, tablets, wines, syrups, and jams are also widely marketed.

In September 2018, A. melanocarpa was approved as a novel food by the National Health Council of China.

2. Traditional and Historical Use

Traditionally, Potawatomi Native Americans used black chokeberry to treat colds, coughs, and fever. Native Americans traditionally used every part of the plant — for nutrition, dyeing materials, curing meats, and medicinal purposes. The Native Americans reportedly used the super-tart fruits to preserve meat. Early settlers took advantage of the high pectin content of the berries, adding them to jams and jellies to make them set.

The plant has been extensively used for hundreds of years by Native Americans for their health-enhancing properties. Lewis and Clark purchased all the highly nutritious, lightweight pemmican they could get to sustain them — as had Native Americans — on their journeys.

Long before its modern resurgence, aronia was used by Native American tribes for both food and medicine. The berries were consumed fresh, dried, or cooked into stews and tonics, valued for their immune-boosting and anti-inflammatory effects. They were also used to treat colds and digestive complaints, and traditional uses are now supported by contemporary research. In recent decades, aronia has gained popularity in Eastern European countries like Poland, Bulgaria, and Russia, where it is commonly consumed as juice, syrup, or wine.

In Russia, Aronia melanocarpa fruits are recommended for internal administration at a dose of 100 g (or 50 g of fresh juice) taken three times a day during 10–30 days as an anti-hypertensive or polyvitamin source.

3. Key Constituents and Active Compounds

3.1 Phenolic Compounds: Overview

Aronia melanocarpa is rich in polyphenols, comprising flavonoids such as anthocyanins, flavanols, and flavonols, and phenolic acids such as chlorogenic acid. These include phenolic compounds, terpenoids, lipids, organic acids, vitamins, sterols, and other substances. The total phenol, flavonoid, and proanthocyanidin levels in Aronia melanocarpa extracts surpass those in blueberry extracts.

3.2 Anthocyanins

Anthocyanins are mainly composed of cyanidin 3-glucoside, 3-galactoside, 3-xyloside, and 3-arabinoside, which are the main source of the black color. On a dry weight basis, anthocyanins were mainly cyanidin-3-galactoside, highest in black aronia (3.4–14.8 mg/g) and lowest in red aronia (0.5–0.8 mg/g) as cyanidin-3-galactoside equivalents. Its berries are rich in polyphenols, particularly anthocyanins such as cyanidin-3-O-galactoside (19–1282 mg/100 g), which are associated with a wide range of bioactivities.

3.3 Proanthocyanidins (Condensed Tannins)

Proanthocyanidins of A. melanocarpa are mainly composed of (−)-epicatechin and trace amounts of (+)-catechin with different mean degrees of polymerization. Aronia proanthocyanidins are mostly polymers with more than 10 monomers. Dimeric and trimeric procyanidins have been isolated from Aronia bark. The bark was found to be a simpler source for isolation of procyanidins compared to berries. The concentration of procyanidins was higher in Aronia bark. Procyanidins B2, B5, and C1 are present both in bark and berries of the Aronia plant.

3.4 Phenolic Acids

Phenolic acids are less diverse than flavonoids, with chlorogenic and neochlorogenic acids being their primary constituents. Besides anthocyanins, A. melanocarpa contains significant amounts of hydroxycinnamic acids: chlorogenic acid and its isomer neochlorogenic acid. They exhibit antioxidant, anti-inflammatory, antidiabetic, and antibacterial activities, thus they can have a significant impact on the health-promoting properties of aronia.

3.5 Flavonols and Other Phenolics

Flavonols present in A. melanocarpa belong to a diverse group of compounds, which mainly consist of quercetin derivatives (quercetin-3-glucoside, 3-galactoside, 3-rutinoside, 3-robinobioside, and 3-vicianoside), isorhamnetin 3-galactoside, 3-glucoside, 3-neohesperidoside, 3-rutinoside, myricetin, and kaempferol 3-galactoside and 3-glucoside. Quercetin and epicatechin, which are minor phenolic compounds, exhibit the highest antioxidant activity.

3.6 Distribution Within the Fruit

The phenolic components of Aronia melanocarpa comprise anthocyanins (mainly cyanidin glycosides), phenolic acids (chlorogenic and neochlorogenic acids), and flavonols (quercetin glycosides). Approximately 30% of the total phenolic compounds are located in the peel and the rest in the flesh and seeds. Peels contain the major part of anthocyanins (73%), while the flesh contains the major part of phenolic acids (78%).

3.7 Other Notable Constituents

The content of the major bioactive components of Aronia berries is relatively high, from 10 mg to 5500 mg per 100 g of the dried fruits, including procyanidins, cyanidin-3-O-galactoside, chlorogenic acid, and quercetin. Examples of promising lead compounds isolated from these berries include cyanidin-3-O-galactoside, chlorogenic acid, quercetin, and ursolic acid. The results of phytochemical analysis have shown that the content of chlorogenic acids and anthocyanins changes during ripening and depends on the time of harvest and the region of cultivation.

4. Mechanisms of Action

4.1 Antioxidant Activity

The antioxidant activity of Aronia melanocarpa is reported to have effects far beyond scavenging free radicals in vivo. These activities have been reported to suppress reactive nitrogen and oxygen species, increase the recovery of antioxidant enzymes, inhibit prooxidants, and influence cellular signaling to regulate antioxidant levels.

4.2 Anti-Inflammatory Signaling

The compounds in aronia help regulate key signaling pathways in the body — such as Nrf2/KEAP1, NF-κB/MAPK, and PI3K/Akt — that control antioxidant defenses, inflammation, and cell survival. Supporting evidence from animal and cellular models highlights the regulation of NF-κB and AMPK signaling pathways, modulation of gut microbiota, and protective effects against metabolic and age-related disorders.

4.3 Vascular and Anti-Atherosclerotic Effects

Aronia berry extracts exert anti-atherosclerotic effects and inhibit VCAM-1 and ICAM-1 gene expression due to particular bioactive compounds — i.e., chlorogenic acids and anthocyanins — though a potential synergistic effect with other compounds such as proanthocyanidins and flavonols cannot be excluded.

4.4 Glycemic Mechanisms

There is evidence that aronia berries may have beneficial effects on type 2 diabetes through enzyme-regulating abilities. Aronia berries are capable of inhibiting α-glucosidase and dipeptidyl peptidase 4 (DPP-4) both in vitro and in vivo in diabetic KKAy mice. Antidiabetic agents with such properties are marketed. α-glucosidase inhibition delays the breakdown of disaccharides in the small intestine and thus the release of glucose into the bloodstream. Inhibition of DPP-4 prevents degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP in turn increase insulin secretion, while only GLP-1 decreases glucagon secretion, leading to lower blood glucose.

4.5 Gut Microbiota Modulation

Thanks to the polyphenols and antioxidant capacity found in Aronia melanocarpa, it has been reported to exhibit positive effects on the gut microbiota, immunomodulatory properties, protection against DNA damage, and anti-inflammatory activity.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health — Blood Pressure and Lipids

Meta-analytic evidence: Daily supplementation with aronia berry extracts for 6–8 weeks significantly reduces systolic blood pressure, a key risk factor for cardiovascular disease, as well as total cholesterol. These effects are most significant in adults over the age of 50 years. This conclusion was drawn from a meta-analysis of controlled clinical trials published in the Journal of Dietary Supplements (Hawkins et al., 2020/2021). The study noted an industry (Artemis International) funding contribution, though the funders were stated to have played no role in data analysis or interpretation.

Conflicting systematic review evidence: A separate systematic review published in Reviews in Diabetic Studies (Christiansen et al., 2022/2023), which searched PubMed, Embase, and Cochrane and identified 17 studies, reached more cautious conclusions. Aronia did not influence body weight, circulating triglycerides, total cholesterol, HDL cholesterol, or blood pressure in the quantitative analysis. The quantitative analysis did reveal a mean reduction in blood glucose of 0.44 mmol/L (P=0.0001) in the treatment group compared with the control group, suggesting that aronia treatment may have a beneficial impact on blood glucose. Treatment durations of 6 weeks to 3 months tended to decrease LDL cholesterol, while shorter treatment durations had no effect. More long-term, high-quality randomized controlled studies are needed to clarify if dietary supplementation with aronia has beneficial effects on cardiometabolic diseases.

Individual randomized controlled trial (pilot): A 6-week pilot randomized human trial evaluated the effectiveness of standardized AM extract supplementation in mitigating CVD risk factors. The human trial demonstrated significant reductions in total cholesterol, LDL cholesterol, and alanine aminotransferase (ALAT) levels in the supplemented group. In vitro studies confirmed AM extract's anti-inflammatory effects, as indicated by reduced pro-inflammatory cytokines and adhesion molecules in human endothelial cells (HUVECs) and PBMCs.

Metabolic syndrome population: After a one-month supplementation with a commercial extract of aronia berries in patients with metabolic syndrome, the overall potential for coagulation, clot formation, and fibrinolysis were found to be decreased significantly, with blood pressure, glycemia, and the lipid profile all being reduced.

RCT in mildly hypercholesterolemic men: A prospective, double-blinded, randomized, crossover clinical trial was conducted in mildly hypercholesterolemic men (n=109). Participants were randomized to supplementation with either aronia or placebo for 90 days, followed by a wash-out. The standardized aronia supplementation comprised three wild Aronia species and the hybrid ×Sorbaronia mitschurinii, standardized to 150 mg anthocyanins daily.

Overall assessment for cardiovascular outcomes: Human intervention trials have shown improved antioxidant status, lipid and glucose metabolism, vascular function, and inflammatory markers. However, some results remain inconclusive due to differences in cultivar, processing, dosage, and individuals. The evidence for blood pressure and cholesterol lowering is promising but not yet definitive; study populations are generally small, trial durations short, and methodological quality variable.

5.2 Blood Glucose, Insulin Resistance, and Type 2 Diabetes

Clinical trial in T2DM patients: Milutinovic et al. tested the effect of three daily doses of 50 mL aronia juice, corresponding to 258 mg anthocyanins, for three months and compared the results to no supplementation in 35 T2DM patients. They observed a significant reduction in LDL cholesterol after aronia supplementation, but only non-significant reductions in fasting blood glucose, hemoglobin A1c (HbA1c), total cholesterol, and triglycerides. Critically, those studies were not blinded, nor randomized.

Triple-blinded RCT: One study was a triple-blinded, triple-crossover study with eight-week intervention periods with fermented aronia extract (FAE), non-fermented aronia extract (AE), and placebo. Extracts were incorporated in snack bars with 37% aronia (FAE or AE) or wheat bran (placebo) and 63% raisins and coconut oil. Pre- and post-treatment fasting blood samples including hemoglobin A1c, fructosamine, insulin, glucose, and glucagon-like peptide-1 were collected.

RCT on cholesterol and glucose (2024): A double-blind, randomized, placebo-controlled intervention trial assessed the impact of chronic aronia juice consumption. Participants consumed either 100 mL of Aronia juice (ARO) or a placebo juice per day for 30 days. Daily consumption of Aronia prevented a rise in cholesterol levels (β = −0.50, p = 0.03) and reduced postprandial glucose (β = −3.03, p < 0.01). This trial had only 14 subjects, limiting its generalizability.

Meta-analysis on body weight and fasting blood sugar (2025/2026): Seven studies were identified and included in this meta-analysis. The findings revealed no significant reductions in fasting blood sugar (WMDs: 0.05 mmol/L, 95% CI: −0.05 to 0.16, p = 0.341), body weight (WMDs: −0.66 kg, 95% CI: −2.54, 1.22, p = 0.494), body mass index, or waist circumference in the Aronia melanocarpa treatment group. Subgroup analysis showed no significant effects on body weight or BMI. The meta-analysis indicates that aronia berry consumption does not affect the aforementioned variables, but further clinical data are needed.

Summary: Aronia melanocarpa berries are rich in antioxidants and possess a high antioxidant capacity. Aronia berries have shown potential in type 2 diabetes mellitus treatment, and previous studies indicate improvements in glycemia after supplementation. Unfortunately, the effectiveness of aronia berries is limited by the low bioavailability of aronia polyphenols, which fermentation could potentially overcome. Overall evidence in the glycemic domain is mixed, and the most rigorous meta-analysis to date finds no significant effect on fasting blood sugar or body weight.

5.3 Antioxidant Status

A meta-analysis of controlled clinical trials revealed that daily supplementation with aronia berry extract for 6–8 weeks led to significant reductions in systolic blood pressure and total cholesterol levels. A previous study revealed that supplementation with polyphenol-rich Aronia melanocarpa significantly downregulated glutathione peroxidase (GSH-Px) activity in the hypertensive group, resulting in total antioxidant capacity changes. This administration significantly reduced blood pressure components and serum malondialdehyde (MDA) compared to the hypertensive group.

5.4 Anti-Inflammatory Effects

Aronia extract markedly decreased the expression of MCP-1 and IL-6 mRNA expression in TNF-α–stimulated HUVECs. In vitro studies have demonstrated that extracts inhibit expression of ICAM-1 and VCAM-1, the predominant endothelial adhesion molecules. These findings are predominantly from cell-culture (in vitro) models. Human clinical data specifically measuring anti-inflammatory biomarkers as primary endpoints are limited.

5.5 Antiviral Activity

Aronia berries contain considerable amounts of bioactive compounds, of which anthocyanins, proanthocyanidins, and other types of flavonoids and phenolic acids all show antiviral activity against influenza viruses. These components inhibit virus replication directly and indirectly, including by blocking viral surface glycoproteins and by stimulating the immune system. Thus, aronia berries could have potential use in the prevention and treatment of influenza. A powder of aronia berries was found to show anti-influenza activity, which could be attributed to phenolic constituents including ellagic acid and myricetin. This evidence is largely in vitro or preclinical; no well-designed human clinical trials on antiviral efficacy have been reported.

5.6 Gut Microbiota

Polyphenol-rich aronia fruits have great potential as a functional food with anti-inflammatory, hypolipidemic, and hypoglycemic biological activities. However, clinical intervention trials investigating the impact of aronia fruit consumption on human health are limited. A randomized, controlled, double-blinded, parallel intervention trial conducted using 14 human subjects measured fecal microbial composition data and mass spectrometry-acquired serum and fecal metabolomic data before and after the intervention. Preliminary data support favorable microbiota modulation, but the trial was very small and short (30 days).

5.7 Metabolic Syndrome

A clinical study investigated the impact of a 4-week supplementation regimen with a standardized aronia extract (SAE) on clinical and biochemical parameters in individuals diagnosed with metabolic syndrome. Increased SAE intake was associated with favorable effects on body weight, total cholesterol, LDL, HDL, blood pressure, and glycemia. This was a prospective controlled but not fully blinded study; independent replication in larger, well-controlled trials is needed.

5.8 Anticancer and Oncological Potential

Numerous health-promoting activities — namely antioxidative, antimutagenic, anticancer, cardioprotective, hepatoprotective, gastroprotective, antidiabetic, anti-inflammatory, antibacterial, antiviral, radioprotective, and immunomodulatory — have been demonstrated for black chokeberry extracts by both in vitro and in vivo studies. Clinical trial investigations for aronia berries and their major components include cancer clinical trials for chlorogenic acid and COVID-19 trial studies for quercetin. However, these refer to trials of isolated compounds rather than aronia fruit or extract itself, and while phenolic compounds are recognized as the primary active components of aronia berries, the specific anti-diabetic, anti-obesity, and neuroprotective agents within these berries have yet to be clearly identified. Further research is also required to investigate ursolic acid, its derivatives, and other constituents of aronia berries that demonstrate potential anti-tumor activity. No clinical trials of aronia extracts as cancer treatments have been completed in humans.

6. Body Systems and Health Areas Associated with Aronia melanocarpa

• Cardiovascular system: Blood pressure regulation, cholesterol reduction (particularly LDL), anti-atherosclerotic endothelial effects, anticoagulant and antithrombotic properties.
• Metabolic/endocrine system: Glycemic regulation, insulin sensitivity, inhibition of carbohydrate-digesting enzymes (α-glucosidase, DPP-4).
• Immune system: Immunomodulation, antiviral activity (predominantly preclinical), stimulation of antioxidant enzyme systems.
• Gastrointestinal system: Gut microbiota modulation; aronia berries could have significant therapeutic potential against inflammatory bowel disease due to their antioxidant and anti-inflammatory capacities as well as their ability to restore the gut microbiota balance (preclinical data).
• Hepatic system: Hepatoprotective effects observed in preclinical models; one clinical pilot study reported reduction of ALT (alanine aminotransferase) levels.
• Neurological system: Neuroprotective effects are an area of preclinical investigation. The specific neuroprotective agents within aronia berries have yet to be clearly identified.

7. Dosage Forms and Dosages Reported in Studies

No universally established therapeutic dose has been defined for Aronia melanocarpa. The following doses have been reported in peer-reviewed studies and reviews:

• Daily supplementation with aronia berry extracts for 6–8 weeks was used in the meta-analysis that showed significant reductions in systolic blood pressure and total cholesterol.
• Daily intake of 500 mg of aronia extract was used in a study that reduced total cholesterol (TC) and LDL-C levels in smokers.
• Three daily doses of 50 mL aronia juice, corresponding to 258 mg anthocyanins, were administered for three months in T2DM patients.
• One standardized aronia supplementation comprised multiple wild Aronia species and was standardized to 150 mg anthocyanins daily over 90 days.
• Participants consumed 100 mL of aronia juice per day for 30 days in one randomized controlled trial.
• In Russia, aronia fruits are recommended for internal administration at 100 g (or 50 g of fresh juice) taken 3 times a day during 10–30 days for anti-hypertensive or polyvitamin purposes.

Dosages used in clinical trials thus range broadly — from 100 mL of juice daily to standardized extracts of 150–500 mg per day — reflecting a lack of consensus on optimal dosing.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile

In vitro, in vivo, and clinical studies indicate that Aronia melanocarpa exerts potent antioxidant, anti-inflammatory, antidiabetic, cardioprotective, anti-obesity, and anticancer effects, attributed mainly to its rich anthocyanin and procyanidin content. The berry has a long history of food use in Eastern Europe without documented population-level toxicity. The possible adverse effects of polyphenols are mostly seen with high-dose supplements or plant extracts consumed without medical supervision. The possibility of interactions of supplements with drugs should be taken into consideration, especially in individuals who use regular medications due to chronic diseases.

8.2 Gastrointestinal Contraindications

Juice and berries are not recommended in the case of gastric ulcer and duodenal ulcer, as well as for hyperacid gastritis. This caution is noted in the Russian pharmacopoeial context.

8.3 Known Drug Interaction Case Report

Rhabdomyolysis developed in a patient receiving chemotherapy after the use of a herbal supplement containing Aronia melanocarpa; sudden weakness, muscle pain, and grade 4 pancytopenia were detected. It was suggested that the aronia inhibited cytochrome P450 enzymes and allowed the drug to reach toxic levels, and the findings improved when the supplement was discontinued (Strippoli et al., 2013). This represents a documented, clinically serious interaction in the context of concurrent cytotoxic chemotherapy and warrants caution for patients undergoing oncologic treatment.

8.4 Allergic Potential

Allergic reactions to aronia berries are extremely rare. Aronia belongs to the Rosaceae family, which also includes apples, pears, and cherries. If a known allergy to Rosaceae fruits exists, caution with aronia is warranted. No cases of anaphylaxis from aronia consumption have been documented in the medical literature.

8.5 Bioavailability Limitations

The effectiveness of aronia berries may be limited by the low bioavailability of aronia polyphenols, which fermentation could potentially overcome. Differences in bioavailability between individual consumers may also contribute to the variability observed in clinical trial results.

8.6 Current State of Evidence — Overall Characterization

This review covers the latest research trends on the positive effects of Aronia melanocarpa on a variety of diseases, including diabetes, cardiovascular disease, and neurological diseases. Many studies have reported the specific effects of anthocyanins and phenolic acids. However, polyphenol monomers and components with potent functional and disease-controlling properties in Aronia melanocarpa should be systematically identified. The human clinical evidence base remains limited in scale and methodological consistency. Most mechanistic knowledge derives from in vitro and animal studies, and the translation of these findings to clinical outcomes in humans requires further large, adequately powered, long-term randomized controlled trials.

References

• Ren Y et al. (2026). A Review of Aronia melanocarpa's Phytochemical Profile, Health Benefits, and Applications in Agri-Food Systems. Foods, 15(10), 1627.
• Arranz S et al. (2022). Aronia Melanocarpa: Identification and Exploitation of Its Phenolic Components. PubMed.
• Kim YM et al. (2024). Functional Activities and Mechanisms of Aronia melanocarpa in Our Health. PMC / Nutrients.
• Krauze M et al. (2025). Aronia Berry (Aronia melanocarpa L.) as a Bioactive Treasure: Insights into Its Health-Promoting Effects. ScienceDirect / Food Bioscience.
• Ren Y, Frank T, Meyer G et al. (2022). Potential Benefits of Black Chokeberry (Aronia melanocarpa) Fruits and Their Constituents in Improving Human Health. Molecules, 27(22), 7823.
• Lohrasbi N et al. (2025/2026). The Effect of Aronia melanocarpa (Chokeberry) on Body Weight and Fasting Blood Sugar: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism.
• Li X et al. (2023). Anthocyanin and proanthocyanidin from Aronia melanocarpa (Michx.) Ell.: Purification, fractionation, and enzyme inhibition. PMC.
• Bielecka M et al. (2020). Aronia melanocarpa Fruits as a Rich Dietary Source of Chlorogenic Acids and Anthocyanins: 1H-NMR, HPLC-DAD, and Chemometric Studies. PMC / Molecules.
• Rugaard Paulsen B et al. (2013). Extracts, Anthocyanins and Procyanidins from Aronia melanocarpa as Radical Scavengers and Enzyme Inhibitors. PMC / Natural Product Communications.
• Bielecka M et al. (2024). Anti-Atherosclerotic Properties of Aronia melanocarpa Extracts Influenced by Their Chemical Composition Associated with the Ripening Stage of the Berries. PMC.
• Zhao Y et al. (2025). Effects of Aronia melanocarpa Tannins on Oxidative Stress and Immune Dysfunction. PMC.
• Ochmian I et al. (2013). Underutilized Chokeberry Accessions Are Rich Sources of Anthocyanins, Flavonoids, Hydroxycinnamic Acids, and Proanthocyanidins. Journal of Agricultural and Food Chemistry.
• Hawkins J, Hires C, Baker C, Keenan L, Bush M. (2021). Daily supplementation with aronia melanocarpa (chokeberry) reduces blood pressure and cholesterol: a meta analysis of controlled clinical trials. Journal of Dietary Supplements, 18(5), 517–530.
• Tasic N et al. (2021). Black chokeberry Aronia melanocarpa extract reduces blood pressure, glycemia and lipid profile in patients with metabolic syndrome: a prospective controlled trial. PubMed / Molecular and Cellular Biochemistry.
• Christiansen CB et al. (2023). Effects of Aronia melanocarpa on Cardiometabolic Diseases: A Systematic Review of Quasi-Design Studies and Randomized Controlled Trials. Reviews in Diabetic Studies.
• Widmer C et al. (2025). Cardiovascular benefits of standardized Aronia melanocarpa extract: Insights from a short-term pilot randomized human trial and cell culture studies. ScienceDirect.
• Lindquist L et al. (2024). Polyphenol-Rich Aronia melanocarpa Fruit Beneficially Impact Cholesterol, Glucose, and Serum and Gut Metabolites: A Randomized Clinical Trial. Foods, 13(17), 2768.
• Christiansen CB et al. (2023). Aronia in the Type 2 Diabetes Treatment Regimen. Nutrients, 15, 4188.
• Persson IA-L. (2017). Antidiabetic Effects of Aronia melanocarpa and Its Other Therapeutic Properties. PMC.
• Szopa A et al. (2026). Aronia Melanocarpa as a Multifunctional Superberry: From Antioxidant Potential to Therapeutic and Nanotechnological Applications. Current Nutrition Reports / PMC.
• Zhao Y et al. (2021). Aronia melanocarpa polysaccharide ameliorates inflammation and aging in mice by modulating the AMPK/SIRT1/NF-κB signaling pathway and gut microbiota. Scientific Reports.
• ScienceDirect Topics: Aronia melanocarpa — Overview.
• Jurendić T & Ščetar M. (2022). Chokeberry (Aronia melanocarpa) as a new functional food relationship with health: an overview. ScienceDirect.
• American Botanical Council HerbClip (2026). Systematic Review Shows No Effect of Aronia Berry on Body Composition and Fasting Blood Glucose in Adult Populations.
• Zhao Y et al. (2022). Aronia melanocarpa (Michx.) Elliott. attenuates dextran sulfate sodium-induced Inflammatory Bowel Disease via regulation of inflammation-related signaling pathways and modulation of the gut microbiota. PubMed.